Science
Proprietary Beta-Cell Death Biomarker
First-in-class molecular signal enabling earlier, more precise detection of pancreatic injury and metabolic disease.
$15 Million Series A Financing
Building the Next Category-Defining
Molecular Diagnostics Platform.
Kihealth is raising a $15 million Series A to accelerate commercialization of its proprietary molecular diagnostics platform, expand laboratory operations, advance FDA regulatory milestones, validate additional disease applications, and scale commercial deployment across the United States and international markets.
Why Now
A rare convergence of science, regulation, and market timing.
Kihealth is entering its Series A at a moment when every foundational element — biomarker, laboratory, regulatory pathway, validation, and commercial infrastructure — is already in place.
Regulatory
FDA Submission Underway
Active regulatory pathway advancing toward clearance and multi-indication expansion.
Operations
Commercial Laboratory Operational
CLIA & COLA-certified high-complexity molecular laboratory delivering clinical-grade results today.
Validation
Academic Validation Expanding
Peer-reviewed evidence, active collaborations, and ongoing multi-site clinical studies with leading institutions.
Platform
Multiple Disease Verticals
Intercept IQ™ scales beyond diabetes into autoimmune, oncology, neurology, and companion diagnostics.
Commercial
Partnerships Already Established
Existing relationships with providers, academic centers, and pharmaceutical partners accelerate market entry.
Market Opportunity
Addressing multi-billion-dollar healthcare markets.
Kihealth sits at the intersection of the largest and fastest-growing segments in modern healthcare — creating a defensible position across science, software, and commercial channels.
12% CAGR
Market Size
$175B+
Precision Medicine
Increasing demand for personalized diagnostics and molecular testing across chronic and complex disease.
TodayProjected Growth
9% CAGR
Market Size
$30–40B+
Molecular Diagnostics
Rapid adoption of high-value molecular testing across metabolic, oncology, and autoimmune disease.
TodayProjected Growth
Global spend
Market Size
$400B+
Diabetes Care
Earlier detection and intervention improve outcomes while dramatically reducing long-term healthcare costs.
TodayProjected Growth
Expanding rapidly
Market Size
$150B+
GLP-1 Therapeutics
Rapid market growth is driving demand for companion diagnostics, patient stratification, and monitoring.
TodayProjected Growth
14% CAGR
Market Size
$10B+
Companion Diagnostics
Diagnostics are becoming inseparable from targeted therapeutics and next-generation precision medicine.
TodayProjected Growth
20%+ CAGR
Market Size
$25B+
AI-Enabled Clinical Decision Support
Fastest-growing segment of healthcare software supporting data-driven, personalized care.
TodayProjected Growth
Competitive Moat
Building durable competitive advantage.
Kihealth's defensibility is engineered across seven reinforcing layers — each independently valuable, together creating a compounding moat.
01
Patent Portfolio
Expanding IP protecting biomarkers, algorithms, software, laboratory processes, and platform architecture.
02
AI Platform
Proprietary machine-learning models translating molecular signal into actionable clinical intelligence.
03
Laboratory Infrastructure
High-complexity CLIA/COLA-certified molecular laboratory built to scale with commercial demand.
04
Academic Partnerships
Collaborations with leading academic medical centers generating durable peer-reviewed evidence.
05
Commercial Partnerships
Provider, distribution, and pharmaceutical relationships accelerating adoption and revenue generation.
06
FDA Regulatory Pathway
Active FDA engagement supporting clearance and progressive expansion across new indications.
07
Integrated Platform
Single technology core supporting many diagnostic applications with compounding operating leverage.
$15M Series A · Use of Proceeds
Strategic use of Series A capital.
Kihealth's $15 million Series A financing is designed as a disciplined investment in enterprise value — accelerating regulatory clearance, commercial rollout, laboratory scale, clinical evidence, and expansion of the Intercept IQ™ platform in parallel.
Illustrative allocation across value drivers
01
FDA Regulatory Advancement
Accelerate FDA submissions and clearance milestones — unlocking reimbursement, credibility, and broad market access.
02
CLIA/COLA Laboratory Expansion
Scale the certified molecular laboratory with automation and capacity to support rising commercial testing volume.
03
Commercial Rollout & Market Expansion
Grow physician adoption, payer coverage, and enterprise channels to accelerate revenue and market penetration.
04
Multi-Center Clinical Validation
Fund pivotal studies across leading academic and clinical centers to strengthen evidence and reimbursement leverage.
05
New Diagnostics on Intercept IQ™
Advance additional disease indications built on the platform, compounding value with every new application.
06
AI & Software Platform
Extend proprietary algorithms, predictive analytics, and clinical decision-support software driving differentiation.
07
Patent & Trademark Portfolio
Deepen IP moats across biomarkers, algorithms, and laboratory processes to protect long-term enterprise value.
08
Manufacturing & Operational Scale
Invest in automation, supply chain, and operations infrastructure to support increasing commercial demand.
Value Creation Roadmap
How Series A capital translates into enterprise value.
A disciplined sequence of milestones — from financing to long-term enterprise value — each unlocking the next.
- 1Series A Financing
- 2Expanded Clinical Validation
- 3FDA Clearance
- 4Commercial Launch
- 5Revenue Growth
- 6Platform Expansion
- 7New Disease Applications
- 8Strategic Partnerships
- 9Long-Term Enterprise Value
Prevention Economics
Earlier detection creates better outcomes — and larger market opportunities.
The commercial case for early-intervention diagnostics is as compelling as the clinical case. Prevention is where the next generation of healthcare value will be created.
- Chronic diseases account for the majority of healthcare spending — a system straining under late-stage treatment costs.
- Earlier intervention meaningfully reduces downstream treatment expense and improves outcomes.
- Molecular diagnostics are increasingly standard components of modern precision medicine.
- Pharmaceutical developers require biomarkers for patient stratification and therapeutic monitoring.
- Healthcare systems are shifting toward prevention, value-based care, and longitudinal monitoring.
Stat 01
90%
of U.S. healthcare spending goes to chronic disease
Stat 02
$4.5T+
annual U.S. healthcare expenditure
Stat 03
3–10×
cost reduction potential with earlier intervention
Stat 04
70%+
of new drug approvals leverage biomarkers
Cost Curve
Detection Stage → Cost
Illustrative: treatment cost rises sharply as disease progresses — early detection compresses lifetime cost of care.
Investment Summary
Why Kihealth.
Ten pillars that together define a durable, scalable precision diagnostics platform positioned to capitalize on the fastest-growing sectors in global healthcare.
Proprietary molecular biomarker platform
First-in-class beta-cell death signal anchoring a multi-indication diagnostics engine.
High-complexity CLIA/COLA laboratory
Operational, scalable lab infrastructure supporting commercial deployment today.
Proprietary AI and predictive analytics
Machine-learning models translating molecular signal into clinical decision-grade output.
Expanding patent and trademark portfolio
Layered IP across biomarkers, algorithms, software, and laboratory processes.
FDA regulatory pathway underway
Active regulatory strategy positioning the platform for clearance and expansion.
Multiple academic validation partners
Peer-reviewed evidence and collaborations with leading academic medical centers.
Established commercial relationships
Provider, distribution, and enterprise channels ready for commercial scale-up.
Companion diagnostic opportunities
Pharmaceutical partnerships supporting patient stratification and therapeutic monitoring.
Scalable platform across many diseases
Single technology core supporting metabolic, autoimmune, oncology, and neurology applications.
Global multi-billion-dollar market
Positioned across precision medicine, molecular diagnostics, and AI-enabled care.
Investor Relations
Request the Series A information package.
Confidential materials are available to accredited investors under NDA.
Kihealth Investor Relations
This page is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any such offer will be made only by means of confidential offering materials to qualified accredited investors in accordance with applicable securities laws. Forward-looking statements regarding Kihealth's platform, pipeline, regulatory plans, and financing activities are subject to risks and uncertainties; actual results may differ materially. Market size and growth figures are illustrative estimates drawn from publicly available industry sources.